Logo image of 22UA.DE

BIONTECH SE-ADR (22UA.DE) Stock Price, Quote, News and Overview

FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR

101.6  -2.5 (-2.4%)

22UA.DE Quote, Performance and Key Statistics

BIONTECH SE-ADR

FRA:22UA (3/7/2025, 7:00:00 PM)

101.6

-2.5 (-2.4%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High124.9
52 Week Low69.7
Market Cap24.36B
Shares239.74M
Float88.26M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-10 2019-10-10


22UA.DE short term performance overview.The bars show the price performance of 22UA.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

22UA.DE long term performance overview.The bars show the price performance of 22UA.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20 -30

The current stock price of 22UA.DE is 101.6 EUR. In the past month the price decreased by -11.03%. In the past year, price increased by 22.5%.

BIONTECH SE-ADR / 22UA Daily stock chart

22UA.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B
1MRNA.MI MODERNA INC N/A 12.34B

About 22UA.DE

Company Profile

22UA logo image BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Company Info

BIONTECH SE-ADR

An der Goldgrube 12

Mainz RHEINLAND-PFALZ DE

Employees: 6133

Company Website: https://www.biontech.com/

Investor Relations: https://investors.biontech.de/

Phone: 4949613190840

BIONTECH SE-ADR / 22UA.DE FAQ

What is the stock price of BIONTECH SE-ADR today?

The current stock price of 22UA.DE is 101.6 EUR. The price decreased by -2.4% in the last trading session.


What is the ticker symbol for BIONTECH SE-ADR stock?

The exchange symbol of BIONTECH SE-ADR is 22UA and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is 22UA.DE stock listed?

22UA.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for BIONTECH SE-ADR stock?

27 analysts have analysed 22UA.DE and the average price target is 134.32 EUR. This implies a price increase of 32.21% is expected in the next year compared to the current price of 101.6. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIONTECH SE-ADR worth?

BIONTECH SE-ADR (22UA.DE) has a market capitalization of 24.36B EUR. This makes 22UA.DE a Large Cap stock.


How many employees does BIONTECH SE-ADR have?

BIONTECH SE-ADR (22UA.DE) currently has 6133 employees.


What are the support and resistance levels for BIONTECH SE-ADR (22UA.DE) stock?

BIONTECH SE-ADR (22UA.DE) has a support level at 101.59 and a resistance level at 112.64. Check the full technical report for a detailed analysis of 22UA.DE support and resistance levels.


Is BIONTECH SE-ADR (22UA.DE) expected to grow?

The Revenue of BIONTECH SE-ADR (22UA.DE) is expected to decline by -38.23% in the next year. Check the estimates tab for more information on the 22UA.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIONTECH SE-ADR (22UA.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIONTECH SE-ADR (22UA.DE) stock pay dividends?

22UA.DE does not pay a dividend.


What is the Price/Earnings (PE) ratio of BIONTECH SE-ADR (22UA.DE)?

BIONTECH SE-ADR (22UA.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).


22UA.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE turns out to be only a medium performer in the overall market: it outperformed 65.34% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

22UA.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to 22UA.DE. 22UA.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

22UA.DE Financial Highlights

Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS decreased by -117.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2.08%
ROE -2.44%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%20.9%
Sales Q2Q%39.04%
EPS 1Y (TTM)-117.52%
Revenue 1Y (TTM)-54.07%

22UA.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 79% to 22UA.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.

For the next year, analysts expect an EPS growth of -185.35% and a revenue growth -38.23% for 22UA.DE


Ownership
Inst Owners22.06%
Ins Owners2.04%
Short Float %N/A
Short RatioN/A
Analysts
Analysts79.26
Price Target134.32 (32.2%)
EPS Next Y-185.35%
Revenue Next Year-38.23%